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The effect of spinal manipulative therapy on pain relief and
function in patients with chronic low back pain: an individual
participant data meta-analysis
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ackground  A 2019 review concluded that spinal manipulative therapy (SMT) results in similar benefit compared to other interventions for
hronic low back pain (LBP). Compared to traditional aggregate analyses individual participant data (IPD) meta-analyses allows for a more
recise estimate of the treatment effect.
urpose  To assess the effect of SMT on pain and function for chronic LBP in a IPD meta-analysis.
ata  sources  Electronic databases from 2000 until April 2016, and reference lists of eligible trials and related reviews.
tudy  selection  Randomized controlled trials (RCT) examining the effect of SMT in adults with chronic LBP compared to any comparator.
ata  extraction  and  data  synthesis  We contacted authors from eligible trials. Two review authors independently conducted the study
election and risk of bias. We used GRADE to assess the quality of the evidence. A one-stage mixed model analysis was conducted. Negative
oint estimates of the mean difference (MD) or standardized mean difference (SMD) favors SMT.
Abbreviations: IPD, individual participant data; RCT, randomized clinical trial; LBP, low back pain; SMT, spinal manipulative therapy; PRISMA-P,
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esults  Of the 42 RCTs fulfilling the inclusion criteria, we obtained IPD from 21 (n  = 4223). Most trials (s = 12, n  = 2249) compared SMT to
ecommended interventions. There is moderate quality evidence that SMT vs  recommended interventions resulted in similar outcomes on pain
MD −3.0, 95%CI: −6.9 to 0.9, 10 trials, 1922 participants) and functional status at one month (SMD: −0.2, 95% CI −0.4 to 0.0, 10 trials, 1939
articipants). Effects at other follow-up measurements were similar. Results for other comparisons (SMT vs  non-recommended interventions;
MT as adjuvant therapy; mobilization vs  manipulation) showed similar findings. SMT vs  sham SMT analysis was not performed, because
e only had data from one study. Sensitivity analyses confirmed these findings.
imitations  Only 50% of the eligible trials were included.
onclusions  Sufficient evidence suggest that SMT provides similar outcomes to recommended interventions, for pain relief and improvement
f functional status. SMT would appear to be a good option for the treatment of chronic LBP.
ystematic Review Registration Number PROSPERO CRD42015025714
 2021 The Author(s). Published by Elsevier Ltd on behalf of Chartered Society of Physiotherapy. This is an open access article under the
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ntroduction
Low back pain (LBP) is the leading cause of pain and
isability worldwide, and has a major socioeconomic impact
1]. Non-pharmacological approaches are the first choice of
reatment as the risk of adverse events is lower than with
harmacological approaches [2]. One non-pharmacological
pproach includes spinal manipulation or mobilization, col-
ectively known as spinal manipulative therapy (SMT). SMT
s used by a variety of heath care providers such as chiroprac-
ors, osteopaths, manual therapists and physiotherapists.
Many systematic reviews and meta-analyses have ana-
ysed the effects of SMT and suggest that it is an effective
ntervention for the reduction of pain and improvement of
unction [3–5]. However, recommendations for SMT in inter-
ational guidelines for chronic LBP are not consistent [6–8].
ince each guideline development group is using the same
vidence, this is likely to be a consequence of differences
n how groups approach appraisal and interpretation of the
vidence.
One disadvantage of traditional meta-analyses, is that
ggregate data are extracted at the study-level and the inves-
igator is dependent upon how the data is analysed and
resented. Individual participant data (IPD) meta-analysis
ircumvents the issues of poor reporting and not correcting
or baseline covariates, because the individual data are avail-
ble, resulting in more precise and potentially, a more valid
stimate of the effect.
Our recent systematic review for SMT for chronic LBP [5]
eflects some of the potential limitations of traditional aggre-
ate meta-analysis. For example, the authors of included
tudies used different definitions of LBP, included a few
ubacute LBP patients, used different frequencies of treat-
ents, and different analytic techniques ranging from a t-test
o sophisticated regression models. In an IPD meta-analysis,
ome of these problems can be resolved.
The specific objective of this IPD meta-analysis was to
ssess the effectiveness of SMT compared to any other
onservative therapy for primary outcomes (i.e. pain and





f life, recovery, return-to-work, medication use and treat-
ent satisfaction) at one, three, six and twelve months in
dults with chronic LBP.
ethods
This study was conducted according to the Preferred
eporting Items of Systematic Reviews and Meta-
nalyses for IPD (PRISMA-IPD) guidelines [9] (Appendix
Table 1). The protocol was registered with PROS-
ERO (https://www.crd.york.ac.uk/prospero/display record.
hp?RecordID=25714) and approved by the Scientific
eview Board of the Vrije Universiteit Amsterdam and by
he Ethical Committee of the VU University Medical Centre
msterdam (Projectnr. 2015.544).
A detailed description of our study design and procedures
as published previously [10]. The methodology presented
ere gives a brief overview.
ata  sources  and  searches
earch  methods  for  identification  of  new  studies
We included RCTs published from the year 2000. We lim-
ted this inclusion, because it is difficult to trace authors
f older trials, and there is a high probability that these
ata would not be accessible. More importantly, more recent
tudies of SMT for low-back pain are of better methodolog-
cal quality. Therefore, it is unlikely that this delineator will
ave introduced undesirable bias [11]. Studies in the 2011
ochrane Review which examined the effect of SMT for
hronic LBP were included [12]. In addition, we updated the
earch in December 2016 following the same procedure used
n the Cochrane review (Appendix eTable 10) [5,10]. This
as supplemented with reference checking of systematic
eviews and meta-analyses, and personal communication. A
ecent update of the search (May 2018) resulted in the identifi-
ation of five new trials [5], all of which were small in size and
onsidered to have a high risk of bias. A update search from
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hree of which are small in size. The two large-sized studies
f which one examined SMT vs recommended therapies and
he other SMT as adjuvant therapy, reported similar results
o ours.
tudy  selection
ype  of  studies  and  participants
nclusion  criteria.  Only randomized clinical trials (RCTs)
ere included. Studies were included if they recruited adults
≥18 years of age) with chronic (≥12 weeks duration) LBP.
BP is defined as LBP not attributed to a specific pathol-
gy (e.g. infection fracture, tumour or radicular syndrome).
articipants with diffuse leg pain due to a low-back condition
ere included as were participants from primary or secondary
are. In those studies where a mixed population was included
e.g. subacute and chronic), where possible, we included only
hose participants with >12 weeks of LBP.
xclusion  criteria.  We excluded studies that: 1) used an
nadequate randomization procedure (e.g. alternate alloca-
ion, allocation based on birth date); 2) included participants
ith LBP and other conditions such as pregnancy or post-
perative participants; 3) tested the immediate effect of a
ingle treatment only; and 4) compared the effects of a multi-
odal therapy including SMT to another therapy or any other
tudy design whereby the contribution of SMT could not be
solated.
ypes of  interventions
xperimental  intervention.  Studies of spinal manipulation
i.e. high-velocity low-amplitude techniques) as well as
obilization (i.e. low-velocity low-amplitude techniques)
ere included.
omparisons.  We analysed the following comparisons: 1)
MT vs  recommended interventions including non-drug
reatment (e.g. exercise), and drug treatment (e.g. NSAIDs);
) SMT vs  non-recommended interventions (e.g. diathermy),
) sham ‘placebo’ SMT; 4) SMT + intervention vs  inter-
ention alone; 5) high-velocity low-amplitude SMT vs
ow-velocity low-amplitude SMT (i.e. manipulation vs  mobi-
ization).
We based the definition of ‘recommended’ and ‘non-
ecommended’ interventions on recent international guide-
ines for LBP from the USA [8], the UK [6], the Netherlands
7] and COST B13 European guidelines [18]. We categorized
n intervention into ‘recommended’ or ‘non-recommended’
hen this was consistently stated in at least two of these
uidelines.ypes of  outcome  measures
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Secondary outcomes included self-reported health-related
uality of life, return-to-work, global improvement (i.e. per-
eived recovery), treatment satisfaction and analgesic use.
ata  extraction  and  quality  of  assessment
isk  of  bias  in  individual  studies
The 13 risk of bias criteria (scored as ‘low risk’, ‘high risk’
r ‘unclear risk’) recommended by the Cochrane Back and
eck group were used (Appendix eTable 2) [19]. The risk
f bias was conducted by two independent reviewers (SMR,
deZ). To adjudicate disagreement, a third reviewer (RO)
as contacted.
Data of all participants was sought from the authors of the
tudies fulfilling the inclusion criteria. We extracted study
haracteristics, patient characteristics, types of outcomes,
uration of follow-up, description of experimental and con-
rol interventions.
reparing  data  for  analyses
We first compared the original data with the published data
o check for completeness and where necessary and possible,
ttempted to resolve any discrepancies. All variables were
armonized in a data harmonization platform [10].
All outcomes were pooled following a decision rule
Appendix eTable 5). All pain scores were converted to a
–100 points pain scale. To allow pooling of different func-
ional status measures, we recoded the individual scores into
-scores for each separate time point using pooled stan-
ard deviations as denominator (Z  score  = xi−x
SD
). Analysing
hese Z-scores resulted in standardized mean differences
SMD’s). To ease interpretation of SMD’s, we converted
hese to a mean difference (MD) for the 24 point Roland
orris Disability Questionnaire (RMDQ), by multiplying
he SMD with the population standard deviation (SD) of






i = sample size for each trial; S  = standard deviation for each
rial).
For quality of life, physical and mental component scales
f SF12 and SF36 were combined.
Other secondary outcomes were all dichotomized
Appendix eTable 5). However, data were often insufficient
less than 3 trials) to perform any analyses for these outcomes.
dverse events were not included in our protocol but we did
xamine these data.
ata  synthesis  and  analysis
All analyses were based on the intention-to-treat (ITT)
rinciple. Our primary analyses consisted of one-stage IPD
eta-analyses for the five main comparisons at one, three,
ix and twelve months follow-up (see protocol) [10]. These
hosen intervals are standard follow-up moments for treat-
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ost-intervention as there was a large variation in duration
nd frequency of treatments among the studies. Furthermore,
any studies contained no follow-up data immediately fol-
owing the end of treatment. Longitudinal analyses for all
ime points simultaneously were not performed as the models
ere deemed too computationally demanding.
Analyses were conducted using a random-effects analy-
is of covariance model adjusting for baseline outcome using
EML (restricted maximum likelihood), where a separated
ntercept and separate residual variance for each study is
pecified. Models extended with a separate baseline adjust-
ent term per trial did not demonstrate convergence in most
nalyses and we omitted them from all analyses [20].
The pooled treatment effect of SMT was estimated using
n MD or SMD (for continuous outcomes) or as an odds ratio
for dichotomous outcomes) including the 95% CI. Nega-
ive MD for pain and SMD for function favours SMT, while
ositive MD for quality of life favours SMT.
We did not assess the effects of imputing missing data
n outcomes. We addressed the missing outcome data (see
esults: characteristics of studies).
ubgroup and  sensitivity  analyses
Subgroup analyses were pre-specified in our protocol [10]
nd conducted for the following variables: 1) type of clini-
ian (i.e. chiropractor vs  other); 2) ‘multi-modal’ SMT (i.e.
MT delivered alone as opposed to in conjunction with other
odalities have limiting or no effect); 3) country where the
tudy was conducted (USA vs  other); 4) only chronic LBP
articipants (some trials included participants with subacute
BP), and 5) only trials with exercise therapy as a compara-
or. We conducted sensitivity analyses for studies: 1) with
ow risk of bias on random sequence generation and alloca-
ion concealment, 2) with overall low risk of bias (defined as
ulfilling six or more of the criteria items); 3) with a follow-
p period of eight weeks (data from eight weeks follow-up
nalysed with the three months instead of one month and 4)
here we were able to reproduce published results.
Furthermore, sensitivity analyses were performed by cal-
ulating functional status scores ourselves instead of using
he received overall score. Also, we examined the different
unctional status measures (e.g. RMDQ) and pain scales (e.g.
verage pain, pain intensity), separately.
Lastly, to examine whether the RCTs included in this
PD meta-analysis were a representative sample of all known
CTs published since 2000, we conducted a two-stage sensi-
ivity analysis wherein we examined the effect sizes of RCTs
ncluded in this IPD meta-analysis vs  those which were eligi-
le for inclusion, but for which no IPD was available (using
ublished aggregate data) [5].
Assessment of clinical relevance was defined as a small,
edium or large effect and based on the recommendationsf the Cochrane Back and Neck group [21,22]. The overall
uality of the evidence for each outcome was evaluated using
RADE [23] adapted for IPD (see Appendix eTable 6).
R
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esults
dentification  of  trials
In total, 43 RCTs met our inclusion criteria, of which
1 (50%) provided data [24–44] (Fig. 1) representing 4223
articipants. In three trials, the results differed from the pub-
ished results for the primary outcomes by more than five
ercent (i.e. 5 points on a 0–100 point Visual analogue scale,
nd 1.2 points for the 0–24 RMDQ), which we determined to
e a relevant difference. Of these, one trial provided only data
rom participants who gave consent to share their data [40].
or another study, we received data for more participants and
onger follow-up than published [38] while for the third study,
aseline data were very similar but our results of the analyses
eviated somewhat from the published results due to differ-
nt patient numbers and use of different statistical techniques;
his was a small trial (n  = 41) and therefore, these deviations
ere not likely to influence the results presented here [41].
haracteristics  of  studies
Of these 21 RCT’s, 12 evaluated the effect of SMT
s recommended interventions of which eight were com-
ared to exercise therapy [26,27,29,30,32–34,38,40–43], one
valuated the effects of SMT vs  sham SMT [44], five eval-
ated the effect of SMT vs  non-recommended interventions
24,31,33,37,39], five evaluated the effect of SMT as an adju-
ant therapy [25,33,35,36,43] and three evaluated the effect
f manipulation vs  mobilization [28,32,39] (Appendix eTable
).
Sample sizes ranged from 21 to 1334 (median = 192;
QR = 45–271). However, some trials included multiple arms,
nd some included non-chronic LBP patients; Therefore, the
ample size for a given comparison should be considered
otentially smaller. The included trials varied with respect
o the recruitment method, type of SMT technique, number
nd duration of treatments and type of practitioner (Appendix
Table 3).
Of the 4223 participants, 2249 were randomized to the
MT group and 1974 to the comparison group. Table 1
resented the patient characteristics at baseline for SMT vs
ecommended interventions. Data for the other comparisons
re tabulated in eTable 7 (Appendix).
Missing data for primary outcomes ranged from 11% at
ne month to 21% at 12 months. The UK BEAM trial pro-
ided the largest dataset (n  = 1334) and as a result, contributed
ost to the missing outcome data (50% of the total amount).
he UK BEAM authors did not find a difference across ran-
omized groups between responders and non-responders and
rop-out appeared to be unrelated to the treatment [43].isk  of  bias
Approximately three quarters of the studies (n = 15)
eported an adequate random sequence generation
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Fig. 1. Flow diagram of study inclusion.
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Table 1
Patient characteristics at baseline for groups receiving SMT vs groups receiving recommended interventions (s = 12; n = 2475).
Demographic data SMT Recommended interventions
Age, mean (SD) years (s = 11, n = 2409) 47 (14) 47 (14)
Sex, n (%) female (s = 11, n = 2412) 667 (57) 684 (55)
Body mass index, mean (SD) (s = 8, n = 1434) 27 (5) 27 (5)
Ethnicity, n (%) white (s = 5, n = 861) 409 (91) 388 (88)
Lifestyle factors
Physical activity, (%) (s = 6, n = 824)
Low (1 or less than once a week) 115 (32) 166 (36)
Medium (2–3× a week) 146 (40) 166 (36)
High (more than 3× a week) 100 (28) 131 (28)
Smoking, n (%) non-smokers (s = 6, n = 1173) 451 (80) 453 (75)
Alcohol use, n (%) * *
Socio-demographics
Marital status, n (%) married; living with a partner (s = 6, n = 1173) 397 (69) 404 (68)
Level of education, n (%) low/middle (s = 7, n = 1672) 600 (68) 534 (68)
Income, n (%) * *
Employment status, n (%) at work (s = 9, n = 2126) 818 (78) 770 (72)
Nature and severity of LBP
Duration of LBP, n (%) less than 12 months (s = 7, n = 1252) 121 (20) 149 (23)
Leg pain, n (%) (s = 5, n = 1038) 320 (59) 281 (57)
Previous LBP treatment received, n (%) (s = 5, n = 930) 258 (28) 218 (23)
Previous physiotherapy for low back pain received, n (%) (s = 5, n = 771) 64 (8) 72 (9)
Previous SMT for low back pain received, n (%) (s = 6, n = 988) 209 (21) 111 (11)
Used medication for low back, n (%) (s = 6, n = 1018) 200 (20) 269 (26)
Non-specific, n (%) * *
Comorbidities * *
Type of treatment * *
Psychosocial factors SMT Control
Depression, n (%) (s = 5, n = 1297) 43 (6) 75 (13)
Treatment preference/expectations * *
Primary outcomes
Pain
Combined pain score at baseline, mean (SD), (s = 12, n = 2441) 49.5 (22.3) 49.8 (21.6)
Combined pain score at one month, mean (SD), (s = 10, n = 1948) 34.2 (23.0) 35.8 (23.9)
Combined pain score at three months, mean (SD), (s = 9, n = 1673) 27.92 (23.0) 32.1 (24.3)
Combined pain score at six months, mean (SD), (s = 8, n = 1321) 27.35 (23.1) 32.3 (23.9)
Combined pain score at twelve months, mean (SD), (s = 10, n = 1816) 31.80 (26.8) 33.3 (25.4)
Functional status
RMDQ sum score at baseline, mean (SD), (s = 9, n = 2174) 9.0 (5.0) 10.1 (5.4)
RMDQ sum score at one month, mean (SD), (s = 8, n = 1760) 5.6 (5.0) 6.7 (5.4)
RMDQ sum score at three months, mean (SD), (s = 8, n = 1648) 4.8 (5.1) 5.5 (5.3)
RMDQ sum score at six months, mean (SD), (s = 8, n = 1348) 5.0 (5.4) 6.3 (6.0)
RMDQ sum score at twelve months, mean (SD), (s = 7, n = 1575) 5.4 (5.7) 6.2 (5.92)
Secondary outcomes
SF36 Physical Component Scale of SF36 at baseline, mean (SD), (s = 5, n = 1362) 40.7 (7.2) 41.1 (7.6)
SF36 Physical Component Scale of SF36 at one month, mean (SD), (s = 3, n = 865) 44.1 (7.9) 45.7 (8.1)
SF36 Physical Component Scale of SF36 at three months weeks, mean (SD), (s = 4, n = 1154) 46.7 (8.2) 46.9 (8.5)
SF36 Physical Component Scale of SF36 at six months, mean (SD), (s = 5, n = 839) 47.3 (7.8) 47.9 (7.7)
SF36 Physical Component Scale of SF36 at twelve months, mean (SD), (s = 5, n = 1249) 46.4 (8.6) 46.8 (8.8)
SF36 Mental Component Scale of SF36 at baseline, mean (SD), (s = 5, n = 1362) 43.8 (9.1) 45.1 (9.6)
SF36 Mental Component Scale of SF36 at one month, mean (SD), (s = 3, n = 865) 45.5 (8.8) 46.9 (8.8)
SF36 Mental Component Scale of SF36 at three months, mean (SD), (s = 4, n = 1154) 46.9 (9.0) 47.3 (9.5)
SF36 Mental Component Scale of SF36 at six months, mean (SD), (s = 5, n = 839) 46.9 (9.1) 48.0 (8.9)
SF36 Mental Component Scale of SF36 at twelve months, mean (SD), (s = 5, n = 1249) 45.7 (8.9) 46.2 (10.0)
Medication use at baseline, n (% medication use) (s = 3, n = 668) 145 (22) 216 (32)
Medication use at one month, n (% medication use) (s = 3, n = 646) 84 (13) 146 (23)
Medication use at three months, n (% medication use) (s = 3, n = 626) 78 (13) 132 (21)
Medication use at six months, n (% medication use) s = 3, n = 593) 67 (11) 143 (24)
Medication use at twelve months weeks, n (% medication use) (s = 3, n = 582) 82 (14) 141 (24)
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nd allocation concealment (Appendix eTable 4)
24–27,29–32,34,37–40,42,43]. Fifteen trials provided
n adequate overview of withdrawals or drop-outs and
ere able to keep these to a minimum for the subsequent
ollow-up measurements [24–29,31,33,34,36–40,44].
ffect  of  SMT  on  primary  and  secondary  outcomes:  one
tage  meta-analysis
Negative point estimates of the mean difference (MD) or
tandardized mean difference (SMD) favours SMT.
) SMT  vs  recommended  Interventions
Pain and function improved by the end of treatment and
his improvement was sustained up to twelve months after
andomization for all groups (Appendix eFigs. 3 and 4).
Primary  outcomes
Pain. There is moderate quality evidence that SMT has
imilar benefit to recommended interventions at all time
oints (largest difference at three months; Table 2).
Functional status. There is moderate quality evidence that
MT has similar benefit to recommended interventions at all
ime points (largest difference at one month; Table 2).
A subgroup analysis for SMT vs  exercise showed similar
esults (see Appendix eTable 8).
Secondary outcomes
There is moderate quality evidence that SMT results in
 medium reduction in medication use compared to recom-
ended interventions at two of the four time points (largest
ifference at six months. For all other secondary analyses,
here is low to high quality evidence that SMT has a similar
enefit to recommended interventions (Table 3).
) SMT  vs  non-recommended  interventions
Primary outcomes
Pain. There is moderate quality evidence that SMT has
imilar benefit compared to non-recommended interventions
t one and six months (largest difference at six months). There
re insufficient data for the three and twelve months analyses
Table 2).
Functional  status: There is moderate quality evidence
hat SMT has similar benefit compared to non-recommended
nterventions at one, three, and six months (largest differ-
nce at six months). There are insufficient data for the twelve
onths analysis (Table 2).
Secondary  outcomes
Quality  of  life
There is low quality evidence that SMT has a similar ben-
fit to non-recommended interventions at one and six months
largest difference at six months). There are insufficient data
or the three and twelve months analyses (Table 3).) SMT  vs  Sham  SMT
The analysis for this comparison was not performed,
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) SMT  + intervention  vs  intervention  alone
Primary outcomes
Pain. There is moderate quality evidence that
MT + intervention has a similar benefit compared to
ntervention alone at one, three and twelve months and
ow quality evidence that SMT has a similar benefit to
ntervention alone at six months (largest difference at one
onth) (Table 2).
Functional  status. There is moderate quality evidence that
MT + intervention has similar benefit compared to inter-
ention alone at one, three and twelve months and low
uality evidence that SMT + intervention has similar bene-
t compared to the intervention alone at six months (largest
ifference at three months) (Table 2).
Secondary  outcomes
Quality  of  life
There is moderate quality evidence that
MT + intervention has similar benefit compared to
he intervention alone at one, three and twelve months
nd low quality evidence that SMT + intervention has
imilar benefit to the intervention alone at 6 months (largest
ifference at twelve months) (Table 3).
) Manipulation  vs  mobilization
Pain. There is moderate quality evidence that manipula-
ion has a similar benefit compared to mobilization at one
onth (Table 2).
Functional  status.  There is moderate quality evidence that
anipulation has a similar benefit compared to mobilization
t one month (Table 2).
There are no data for the other time points and secondary
utcomes.
ubgroup  and  sensitivity  analyses
The results from all one-stage sensitivity analyses suggest
imilar results for pain and functional status at all time points
Appendix eTable 8).
We found no differences in pain and functional sta-
us between RCTs included and eleven eligible RCTs not
ncluded in the IPD repository (Table 4 and Appendix eTable
). The results of the two-stage analysis were comparable
ith the one-stage analysis. Sensitivity analysis, including
tudies published since 2016, did not change our results.
iscussion
Our results suggest there is moderate quality evidence
hat SMT has similar effects as recommended treatments
or pain reduction and improved functional status at short- intermediate- and long-term follow-up. Additionally, there
s moderate evidence that SMT has similar effects for pain
elief and improvement in function when compared to non-
ecommended therapies and when examined as an adjuvant
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Table 2
Main treatment effects and GRADE summary of findings for all comparisons for the primary outcomes. Regression coefficients () and 95% confidence
intervals (CI) of the intervention effects of random-effect models adjusted for baseline using REML (one stage analysis) are presented.
Comparison 1: SMT vs recommended therapies




1 month MD −3.0, 95% CI −6.9 to 0.9 10 1922 Moderate (inconsistency)
3 months MD −6.6, 95% CI −13.0 to −0.2 9 1647 Moderate (inconsistency)
6 months MD −5.6, 95% CI −9.6 to −1.5 8 1321 Moderate (inconsistency)
12 months MD −2.5, 95% CI −7.1 to 2.1 10 1791 Moderate (inconsistency)
Outcome: functional status SMD converted to a MD on
the 24 point RMDQ scale
1 month SMD −0.2, 95% CI −0.4 to 0.0 10 1939 Moderate (inconsistency) −0.8
3 months SMD −0.1, 95% CI −0.4 to 0.1 11 1892 Moderate (inconsistency) −0.6
6 months SMD −0.2, 95% CI −0.3 to 0.0 9 1490 Moderate (inconsistency) −0.8
12 months SMD −0.1, 95% CI −0.3 to 0.1 10 1826 Moderate (inconsistency) −0.5
Comparison 2: SMT vs non-recommended therapies
Outcome: paina
1 month MD −6.6 95% CI −10. 8 to −2.3 5 755 Moderate (inconsistency)
3 months Not enough data
6 months MD −8.3, 95% CI −20.5 to 3.8 3 419 Moderate (imprecision)
12 months Not enough data
Outcome: functional status SMD converted to a MD on
the 24 point RMDQ scale
1 month SMD −0.3, 95% CI −0.6 to 0.0 5 835 Moderate (inconsistency) −0.6
3 months SMD −0.0, 95% CI −0.8 to 0.7 2 375 Moderate (inconsistency) −0.9c
6 months SMD −0.3, 95% CI −0.6 to −0.0 3 414 Moderate (imprecision) −0.9
12 months Not enough data
Comparison 3: SMT vs sham SMT
No results only data of one study
Comparison 4: SMT + intervention vs intervention alone
Outcome: paina
1 month MD −7.44, 95% CI −12.7 to −2.1 5 762 Moderate (inconsistency)
3 months MD −5.2, 95% CI −11.0 to 0.7 2 619 Moderate (inconsistency)
6 months MD −1.4, 95% CI −6.7 to 3.8 2 222 Low (inconsistency, imprecision)
12 months MD −2.2, 95% CI −5.9 to 1.4 2 603 Moderate (inconsistency)
Outcome: functional statusb
1 month MD −0.6, 95% CI −2.3 to 1.1 a 4 746 Moderate (inconsistency)
3 months MD −1.3, 95% CI −2.6 to −0.1a 3 681 Moderate (inconsistency)
6 months MD −1.0, 95% CI −2.1 to 0.1a 2 218 Low (imprecision, inconsistency)
12 months MD −0.9, 95% CI −1.6 to −0.2a 2 626 Moderate (inconsistency)
Comparison 5: Manipulation vs mobilization
Outcome: pain
1 month MD −1.5, 95% CI −6.8 to 3.9 3 321 Moderate (limitations)
Not enough data for other time points
Outcome: Functional status SMD converted to a MD on
the 24 point RMDQ scale
1 month SMD 0.0, 95% CI −0.0 to 0.1 3 356 Moderate (limitations) −0.6
Not enough data for other time points
Negative difference in effect indicates higher estimated decrease in pain or improvements in function for SMT group compared to the control.
MD = mean difference of combined pain score on a 0–100 scale.
SMD = standardized mean difference of combined functional status score.
a Pain measured on a 0–100 point scale.
b All studies in the SMT + intervention vs intervention alone measured Roland Morris Disability questionnaire, therefore we use a mean difference.
c Based on one small study.
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Table 3
Main treatment effects and GRADE summary of findings for all secondary outcomes.
Comparison 1: SMT vs recommended therapies
Time measurement Difference in effect (95% CI) # studies N Quality of the evidence (and
reason for downgrading)
Outcome: Quality of life: Physical Component Scale of SF36 and SF12 combined
1 month MD −0.6, 95% CI −1.4 to 0.1 4 844 High
3 months MD −0.2, 95% CI −1.0 to 0.7 3 967 High
6 months MD −0.3, 95% CI −1.5 to 0.91 4 688 High
12 months MD 0.1, 95% CI −0.8 to 1.0 4 1055 High
Outcome: Mental Component Scale of SF36 and SF12 combined
1 month MD 0.4, 95% CI −0.4 to 1.2 4 844 High
3 months MD 0.8, 95% CI −0.0 to 1.6 3 967 High
6 months MD −0.1, 95% CI −1.4 to 1.2 4 688 High
12 months MD 0.5, 95% CI −0.9to 2.0 4 1055 High
Outcome: Recoverya: Yes vs No
1 month OR 1.3, 95% CI 0.9 to 1.9 2 499 Moderate (inconsistency)
3 months OR 1.2, 95% CI 0.8 to 1.8 3 538 Moderate (inconsistency)
6 months OR 1.1, 95% CI 0.8 to 1.6 3 651 Moderate (inconsistency)
12 months OR 0.8, 95% CI 0.5 to 1.2 2 445 Moderate (inconsistency)
Outcome: Medication Usea: Yes vs No
1 month OR 0.7, 95% CI 0.5 to 1.0 3 646 Moderate (inconsistency)
3 months OR 0.7, 95% CI 0.4 to 1.2 3 626 Moderate (inconsistency)
6 months OR 0.5, 95% CI 0.3 to 0.9 3 593 Moderate (inconsistency)
12 months OR 0.7, 95% CI 0.3 to 1.3 3 582 Moderate (inconsistency)
Outcome: Return to worka: Yes vs No
1 month Not enough data
3 months OR 1.0, 95% CI 0.5 to 1.9 3 190 Low (inconsistency,
imprecision)
6 months OR 0.6, 95% CI 0.3 to 1.3 3 189 Low (inconsistency,
imprecision)
12 months OR 1.3, 95% CI 0.6 to 2.7 3 180 Low (inconsistency,
imprecision)
Outcome: Satisfactiona: Yes vs No
1 month OR 0. 8, 95% CI 0.4 to 1.6) 2 319 Low (inconsistency,
imprecision)
3 months OR 6.6, 95% CI 1.5 to 29.9 2 429 Low (inconsistency,
imprecision)
6 months Not enough data
12 months Not enough data
Comparison 2: SMT vs non-recommended therapies
Outcome: Quality of life: Physical Component Scale of SF36 and SF12 combined
1 month MD 0.4, 95% CI −0.8 to 1.6 3 345 Low (inconsistency, imprecision)
3 months Not enough data
6 months MD −0.1, 95% CI −2.5 to 2.2 2 202 Low (inconsistency, imprecision)
12 months Not enough data
Outcome: Quality of life: Mental Component Scale of SF36 and SF12 combined
1 month MD 1.0, 95% CI −3.1; 5.2 3 345 Low (inconsistency, imprecision)
3 months Not enough data
6 months MD 1.7, 95% CI −0.6; 4.0 2 202 Low (inconsistency, imprecision)
12 months Not enough data
Other outcomes not enough data
Comparison 3: SMT vs sham SMT
No results only data of one study
Comparison 4: SMT + intervention vs intervention alone
Outcome: Quality of life: Physical Component Scale of SF36 and SF12 combined
1 month MD 0.1, 95% CI −1.1 to 1.5 3 708 Moderate (inconsistency)
3 months MD 0.3, 95% CI −0.7 to 1.3 2 619 Moderate (inconsistency)
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Table 3 (Continued)
Comparison 1: SMT vs recommended therapies
Time measurement Difference in effect (95% CI) # studies N Quality of the evidence (and
reason for downgrading)
6 months MD −1.4, 95% CI −2.9 to 0.1 2 221 Low (inconsistency,
imprecision)
12 months MD −2.2, 95% CI −5.9 to 1.4 2 603 Moderate (inconsistency)
Outcome: Quality of life: Mental
Component Scale of SF36 and
SF12 combined
1 month MD −0.2, 95% CI −1.6 to 1.2 3 708 Moderate (inconsistency)
3 months MD 1.9, 95% CI −0.7 to 4.5 2 619 Moderate (inconsistency)
6 months MD 1.8, 95% CI −0.1 to 3.7 2 221 Low (inconsistency,
imprecision)
12 months MD 1.0, 95% CI −0.3 to 2.2 2 605 Moderate (inconsistency)
Other outcomes not enough data
Comparison 5: Manipulation vs mobilization
All outcomes not enough data
Positive difference in effect indicates higher increased quality of health for SMT group compared to the control.
MD = mean difference.
OR = odds ratio.
a Recovery was classified as ‘recovered’ if the participant scored more than 50% improvement or were (much) better or had no symptoms. Medication use
was classified for those using taking any using medication for LBP, while not taking any medication was classified as no medication use. Return to work was
classified as participants had returned to work or if there were no sick days recorded. Satisfaction was classified as ‘satisfied with care’ if participants were





















































herapy. We have no results for the SMT vs  sham compari-
on, because we could only include one study. Finally, there
s moderate quality evidence that manipulation has similar
ffects as mobilisation.
Our results are consistent with the recently published
ggregate data review [5] and with other recently published
ystematic reviews [4,45,46].
It is somewhat difficult to interpret these findings,
articularly when SMT demonstrates similar effects to
ecommended and non-recommended therapies or when
xamined as an adjuvant therapy. This appears confusing
nd requires explanation. Firstly, most studies we identified
xamined the effect of SMT vs  recommended therapies. In
eneral, these studies were larger, had more data on follow-
p time-points and were of better methodological quality (i.e.
ow risk of bias) than the studies in the other comparisons.
eaning, these findings were more robust and therefore, we
ave more confidence in their effect estimate. Even though
or all these comparisons, there is generally moderate qual-
ty evidence according to GRADE. While there are general
uidelines for applying GRADE, there is no consensus. For
xample, we used a general rule-of-thumb when evaluating
imprecision’ in accordance with what might be considered
n ‘optimal information size. Applying a more stringent opti-
al information size would result in lower quality evidence
or SMT vs  non-recommended therapies or SMT as an adju-
ant therapy, but not when applying this criterion to SMT vs
ecommended therapies (because the latter analyses included




ions into recommended or non-recommended interventions
as not always straightforward (e.g. myofascial therapy), and
herefore, open for interpretation. While a sensitivity analy-
is could have helped to resolve this issue, the data were not
ufficiently robust to make this possible. Lastly, the catego-
ization of an intervention as ‘non-recommended’ does not
mply that these interventions do not have an effect or are
angerous or ill-advised. While trials whereby patients are
blinded’ (i.e. sham) would help to resolve this issue; in our
stimation, no single study was adequately able to do so. An
mportant difference of our IPD analysis compared to tradi-
ional aggregate meta-analyses is that we could adjust for the
ovariates, baseline pain and functional status, and were not
ependent upon how these data were reported in the original
ublications. This has increased precision of our estimates
ompared to aggregate data meta analyses, but did not lead
o a different conclusion for the main effects.
It will be difficult to justify the required financial and
articipant resources for further trials comparing SMT vs
urrent recommended therapies, as this is unlikely to change
ur overall conclusions. Others have previously made the
ame observation with regard to trials of exercise treatment
or low back pain. A 2019 IPD meta-analysis of exercise
herapy for low back pain has also produced precise esti-
ates for effectiveness [47]. Therefore, future studies should
ocus on cost-effectiveness, optimal dosage, delivery route
o minimize side-effects, specificity of the location treated
nd maximize the non-specific effects of care, instead of
eproducing the same type of trials.
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Table 4
Representativeness of the pooled effects of studies providing data for the IPD study and those not providing data. Two stage analysis; SMT vs recommended
therapies.







Combined pain score one month
All eligible studies 16 −2.4 (−4.9; 0.1) 66% <0.001 −2.4 (−11.6; 6.9)
Studies providing data 10 −2.5 (−5.9; 0.9) 75% <0.001 −2.7 (−13.8;8.8)
Studies not providing data 6 −2.2 (−6.1; 1.7) 55% 0.02 −2.218 (−12.9; 8.5)
Combined pain score three months
All eligible studies 14 −3.1 (−7.0; 0.8) 80% <0.001 −3.1 (−18.6; 12.4)
Studies providing data 9 −5.9 (−11.4; −0.5) 86% <0.001 −5.9 (−25.0; 13.0)
Studies not providing data 5 1.1 (−2.7; 4.9) 29% 0.196 1.1 (−7.4; 9.6)
Combined pain score six months
All eligible studies 13 −4.1 (−6.7; −1.6) 66% <0.001 −4.1 (−13.5; 5.2)
Studies providing data 8 −4.8 (−8.9; −0.6) 72% 0.001 −4.8 (−17.8;8.3)
Studies not providing data 5 −3.5 (−7.0; −0.1) 61% 0.009 −3.5 (−13.8; −6.4)
Combined pain score twelve months
All eligible studies 12 −1.8 (−4.8; 1.3) 71% <0.001 −1.8 (−12.5; 9.0)
Studies providing data 10 −2.1 (−6.5; 2.2) 79% <0.001 −2.1 (−16.8; 12.5)
Studies not providing data 2 −0.9 (−3.5; 1.8) 0% 0.6 −0.9 (−6.7; 5.0)
Functional status Difference in Z-score
Combined Functional Status one month
All eligible studies 13 −0.2 (−0.3; −0.0) 49% 0.014 −0.2 (−0.6; 0.3)
Studies providing data 9 −0.3 (−0.5; −0.0) 65% 0.003 −0.3 (−1.0; 0.4)
Studies not providing data 4 −0.1 (−0.2; 0.0) 0% 0.739 −0.1 (−0.2; 0.1)
Combined Functional Status three months
All eligible studies 15 −0.1 (−0.2; 0.1) 75% <0.001 −0.1 (−0.8; 0.7)
Studies providing data 11 −0.2 (−0.4; 0.0) 79% <0.001 −0.2 (−0.9; 0.6)
Studies not providing data 4 0.2 (−0.1; 0.4) 45% 0.089 0.2 (−0.5; 0.8)
Combined Functional Status six months
All eligible studies 13 −0.1 (−0.2; 0.0) 56% 0.002 −0.1 (−0.6; 0.4)
Studies providing data 9 −0.2 (−0.4; −0.0) 69% 0.001 −0.2 (−0.9; 0.5)
Studies not providing data 4 0.0 (−0.1; 0.1) 0% 0.778 0.0 (−0.1; 0.2)
Combined Functional Status twelve months
All eligible studies 13 −0.2 (−0.3; 0.1) 72% <0.001 −0.2 (−0.7; 0.4)
Studies providing data 10 −0.2 (−0.4; 0.1) 79% <0.001 −0.2 (−0.9; 0.6)
Studies not providing data 3 −0.1 (−0.3; 0.1) 43% 0.132 −0.1 (−0.7; 0.5)
























I = confidence interval; I = I statistic, which is the percentage of total v
oderate, and 75% high heterogeneity.
trengths  and  limitations
The most important strength is the sample size and the
iversity of studies, meaning these results are likely to be
roadly generalizable to clinical practice. On the other hand,
his diversity in studies led to a difference in methodological
uality and types of outcomes and covariates across trials
nd introduced statistical heterogeneity, which can intro-
uce difficulties in interpreting the data. We investigated this
iversity with sensitivity analyses and two-stage analyses for
rimary outcomes at all follow-up measurements, but could
ot explain the statistical heterogeneity. Our understanding of
he effects of SMT would improve if we had an understanding
f the aetiology of LBP and how SMT works.
r
o
 that can be explained by heterogeneity, and 25% is considered low, 50%
The most important limitation is potential selection bias.
e included only 50% of the eligible trials, which is com-
arable to other IPD studies [47,48]. In a two-stage analysis
e examined the effect sizes of those that were eligible but
id not provide data. Results suggest only small differences
etween included studies and those for which we were unable
o source the original data, indicating that the RCTs included
re likely to be a representative sample of all published stud-
es. Also, the range of studies based upon publication date and
ethodological quality of the studies we included is compa-
able with the non-included studies in the recently published
eview [5]. Therefore, this facilitates an effective comparison
f interventions across trials.
















































• Randomised controlled trials of varying methodolog-
ical quality and size have examined the benefits and
harms of spinal manipulative therapy (SMT) for the
treatment of chronic low back pain. These trials have
been summarised in systematic reviews with varying
results. SMT is not currently recommended as a first
line treatment for chronic low back pain and its effects
are uncertain.
• SMT is a good option for the treatment of chronic low
back pain.
• Future trials of SMT for low back pain should include
an economic evaluation and a better description of the
qualitative and quantitative components of SMT (e.g.
context of the visit, patient beliefs, and preferences
and factors that are likely to influence treatment).
Future initiatives should also focus on standardizing
the manner in which inclusion and exclusion criteria,
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Also, our review differs slightly from our protocol with
egard to the classification of the comparator. In our proto-
ol, we classified therapies into effective and non-effective,
hereas in this review we classified them into recommended
nd non-recommended therapies. It was thought this would
est help translation of findings to clinical practice. This did
ot affect the reported result, but was more a wording differ-
nce. Finally, longitudinal analyses would have provided us
ith more information on the individual pattern of changes
ver time. In the future, these can be run, when programs are
ble to process these large amounts of data.
mplications  for  clinicians
SMT is similarly effective as recommended and non-
ecommended interventions and when added an adjuvant
herapy, in reducing pain and improving function in patients
ith chronic LBP. For patients with chronic LBP, SMT is a
reatment option. SMT can be delivered as a standalone ther-
py, although it is typically offered within the constructs of
 broader treatment package, together with exercise therapy
r combined with usual care, as is recommended in recent
ational guidelines for low back pain [6–8]. This is impor-
ant because SMT is by nature a passive treatment. Therefore,
o prevent inappropriate behaviour and to empower patients
o take control of their condition it is vital that practitioners
mpart evidence-based messages about passive interventions
uch as SMT. The choice of treatment should be the result of
 shared decision-making process, taking patient preferences
nd clinicians experience and skills into account. No more
esearch is needed to support these recommendations. Further
imilar research is unlikely to change these conclusions.
Adverse events were often not recorded and when
ecorded, were measured differently across trials. Conse-
uently, we were not able to pool these data. These data
id not provide more information than the adverse events
escribed in our systematic review of aggregate data [5].
onclusion/clinical  implication
Sufficient evidence suggest that SMT provides similar
utcomes to recommended therapies for pain relief and
mprovement of functional status. SMT would appear to be
 good option for the treatment of chronic LBP.
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